Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Piera, Viero"'
Autor:
Luigi Rigacci, Roberta Battistini, Sofia Kovalchuk, Valerio Zoli, Benedetta Puccini, Andrea Evangelista, Luca Arcaini, Leonardo Flenghi, Carlo Visco, Michael Mian, Alice Di Rocco, Claudia Peracchio, Manuel Gotti, Maria Chiara Tisi, Francesca Palombi, Samantha Pozzi, Daniela Gioia, Piera Viero, Maurizio Martelli
Publikováno v:
Hematological Oncology. 40:609-616
Salvage immunochemotherapy and transplant consolidation is the standard treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We tested a combination of Obinutuzumab and DHAP for treating R/R DLBCL. The primary end point w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f8712f0929a08832d12510bbc132946
https://doi.org/10.1002/hon.3028
https://doi.org/10.1002/hon.3028
Autor:
Luigi, Rigacci, Roberta, Battistini, Sofia, Kovalchuk, Valerio, Zoli, Benedetta, Puccini, Andrea, Evangelista, Luca, Arcaini, Leonardo, Flenghi, Visco, Carlo, Mian, Michael, Alice Di Rocco, Claudia, Peracchio, Manuel, Gotti, Maria Chiara Tisi, Francesca, Palombi, Samantha, Pozzi, Gioia, Daniela, Piera, Viero, Maurizio, Martelli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1943::7df9e65e2fc5c905ab4e65dfd077a6b0
http://hdl.handle.net/11562/1073709
http://hdl.handle.net/11562/1073709
Autor:
Elena Maino, Anna Maria Scattolin, Piera Viero, Rosaria Sancetta, Anna Pascarella, Michele Vespignani, Renato Bassan
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 7, Iss 1, Pp e2015001-e2015001 (2015)
The introduction of newer cytotoxic monoclonal antibodies and the chimeric antigen receptor-modified T-cells is opening a new age in the management of B-lineage adult acute lymphoblastic leukemia. This therapeutic change must be very positively ackno
Externí odkaz:
https://doaj.org/article/be7007a895c04084889b54d2eb8f3276
Autor:
Orietta Spinelli, Manuela Tosi, Barbara Peruta, Marie Lorena Guinea Montalvo, Elena Maino, Anna Maria Scattolin, Margherita Parolini, Piera Viero, Alessandro Rambaldi, Renato Bassan
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 6, Iss 1, Pp e2014062-e2014062 (2014)
Acute lymphoblastic leukemia (ALL) is curable in about 40-50% of adult patients, however this is subject to ample variations owing to several host- and disease-related prognostic characteristics. Currently, the study of minimal residual disease (MRD)
Externí odkaz:
https://doaj.org/article/bc42b579facf44e2a47e43a0f0dd527a
Autor:
Federico Fallanca, Roberto Sorasio, Umberto Ficola, Silvia Bolis, Guido Gini, Simonetta Viviani, Alessandra Romano, Piera Viero, Roberta Zanotti, Michele Cimminiello, Luca Guerra, Sara Oppi, Andrea Gallamini, Alessandro Rambaldi, Caterina Patti, Marco Picardi, Roberta Battistini, Livio Trentin, Andrea Rossi, Corrado Tarella, Corrado Schiavotto, Antonino Mulè, Maria Cantonetti, Chiara Pavoni, Stephane Chauvie
PURPOSE To investigate the role of consolidation radiotherapy (cRT) in advanced-stage Hodgkin lymphoma (HL) presenting at baseline with a large nodal mass (LNM) in complete metabolic response after doxorubicin, bleomycin, vinblastine, and dacarbazine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::455b594f83198e89f5d69cd3f44bc4d0
http://hdl.handle.net/11588/823892
http://hdl.handle.net/11588/823892
Autor:
Antonella Vitale, Maria-Cristina Puzzolo, Paolo Di Bartolomeo, Martina Canichella, Maria-Stefania De Propris, Sabina Chiaretti, Piera Viero, Gimema Investigators, Massimiliano Bonifacio, Alessandra Mancino, Marco Vignetti, Alfonso Piciocchi, Anna Guarini, Monia Lunghi, Alessandro Rambaldi, Felicetto Ferrara, Francesco Fabbiano, Loredana Elia, Renato Bassan, Nicola Fracchiolla, Robin Foà
Background Outcomes in patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa04908f4af6dbfd468b9810ce0649a
http://hdl.handle.net/11573/1623996
http://hdl.handle.net/11573/1623996
Autor:
Piera Viero, Francesca Gianni, Rosaria Sancetta, Francesca Carobolante, Paola Stefanoni, Renato Bassan, Tamara Intermesoli, Alessandro Rambaldi, Elena Maino, Manuela Tosi, Annamaria Scattolin, Orietta Spinelli
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:S2-S9
The study of minimal residual disease (MRD) in adult patients with acute lymphoblastic leukemia (ALL) allows a greater refinement of the individual risk classification and is the best support for risk-specific therapy with or without allogeneic hemat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b5409badd54842c69f5f63af85433d6
https://doi.org/10.1016/j.clml.2017.02.019
https://doi.org/10.1016/j.clml.2017.02.019
Autor:
Matteo Leoncin, Giulia Perali, Piera Viero, Luca Frison, Manuela Tosi, Cristina Skert, Federico Lussana, Alessandro Rambaldi, Francesca Carobolante, Chiara Pavoni, Renato Bassan, Roberta Cavagna, Orietta Spinelli, Tamara Intermesoli
Publikováno v:
Cancers
Cancers, Vol 13, Iss 2108, p 2108 (2021)
Cancers, Vol 13, Iss 2108, p 2108 (2021)
Simple Summary In acute lymphoblastic leukemia (ALL), once a complete remission is achieved following induction chemotherapy, the study of submicroscopic minimal residual disease (MRD) represents a highly sensitive tool to assess the efficacy of earl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e490c7ac6f0af10e81a266acafa10e8
https://doi.org/10.3390/cancers13092108
https://doi.org/10.3390/cancers13092108
Autor:
Massimo Dozzo, Piera Viero, Francesca Carobolante, Annamaria Scattolin, Elena Maino, Renato Bassan, Pietro Maria Donisi, Rosaria Sancetta
Publikováno v:
Adolescent Health, Medicine and Therapeutics
About one-half of all Burkitt lymphoma (BL) patients are younger than 40 years, and one-third belong to the adolescent and young adult (AYA) subset, defined by an age between 15 and 25–40 years, based on selection criteria used in different reports
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6598fe70b9befae76b569bc33ff6f2a1
https://doi.org/10.2147/ahmt.s94170
https://doi.org/10.2147/ahmt.s94170
Autor:
Piera Viero, Simonetta Viviani, Giorgio La Nasa, A. Romano, D. Gottardi, Andrés J.M. Ferreri, Paolo Corradini, Livio Trentin, Alberto Biggi, Federico Fallanca, Maria Cantonetti, G. Gini, Atto Billio, Agostino Chiaravalloti, Giuseppe Prosperini, Davide Rapezzi, A. Mulè, Silvia Bolis, R. Zanotti, Marco Picardi, Chiara Pavoni, Guido Parvis, Corrado Tarella, Paolo Gavarotti, Alessandro Massimo Gianni, Maurizio Miglino, Fabrizio Bergesio, Alessandro Rambaldi, S. Chauvie, Abraham Avigdor, Roberta Battistini, Andrea Gallamini, Michele Gregianin, Andrea Rossi, Corrado Schiavotto, Umberto Ficola, Michele Cimminiello, C. Patti
Purpose To investigate the progression-free survival (PFS) of patients with advanced Hodgkin lymphoma (HL) after a risk-adapted treatment strategy that was based on a positive positron emission tomography scan performed after two doxorubicin, vinblas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d931ddc70a8cbce523dd881be6afda2b
https://hdl.handle.net/20.500.11769/542310
https://hdl.handle.net/20.500.11769/542310